GT Biopharma GTBP
NASDAQ GTBP
$3.72 -0.12 (-3.12%)
At close: Nov 13, 2026 · 4:00 PM EST

GT Biopharma (GTBP) Receivables (2009 - 2014)

Updated

GT Biopharma's Receivables was $5,000 in Q2 2014, down 83.3% from the prior quarter.

Analysis

GT Biopharma (GTBP) Receivables (2009 - 2014) Analysis & Trends

At the end of FY2013, Receivables at GT Biopharma came in at $40,000.

  • The Q2 2014 figure marks the lowest quarterly Receivables since Q1 2009.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn 25.23 Bn
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn 18.99 Bn
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn 13.51 Bn
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn 12.74 Bn
5 Novartis Ag 306.35 Bn 279.93 Bn - -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn 16.16 Bn
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn 10.35 Bn
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn 5.01 Bn
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn 14.19 Bn
10 GT Biopharma 6.65 Mn -16.58 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2014 5,000.00
Mar 31, 2014 30,000.00
Dec 31, 2013 40,000.00
Jun 30, 2009 10,000.00
Mar 31, 2009 4,000.00
API Access

GT Biopharma Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables&ticker=GTBP&period=max&api_key=YOUR_API_KEY